Lilly’s tirzepatide cuts diabetes risk, study data show

Weekly injections of tirzepatide, the drug Eli Lilly sells as Mounjaro and Zepbound, substantially lowered the likelihood people who received it in a clinical trial developed diabetes, according to results the company disclosed Tuesday.